1-3 of 3
Umang Swami
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

External Validation of Association of Baseline Circulating Tumor Cell Counts with Survival Outcomes in Men with Metastatic Castration-Sensitive Prostate Cancer

Umang Swami, Nicolas Sayegh, Yeonjung Jo, Benjamin Haaland, Taylor Ryan McFarland, Roberto H. Nussenzveig, Divyam Goel, Deepika Sirohi, Andrew W. Hahn, Benjamin L. Maughan, Amir Goldkorn, Neeraj Agarwal
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (12): 1857–1861.
https://doi.org/10.1158/1535-7163.MCT-22-0020
Published: 02 December 2022
View article titled, External Validation of Association of Baseline Circulating Tumor Cell Counts with Survival Outcomes in Men with Metastatic Castration-Sensitive Prostate Cancer
Open the PDF for External Validation of Association of Baseline Circulating Tumor Cell Counts with Survival Outcomes in Men with Metastatic Castration-Sensitive Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract P012: Genomic and clinical correlates of overall survival (OS) in men with newly diagnosed metastatic castration-sensitive prostate cancer (mCSPC) undergoing intensified androgen deprivation therapy (ADT)

Nicolas Sayegh, Bennet Peterson, Roberto Nussenzveig, Adam Kessel, Taylor Ryan McFarland, Andrew Warren Hahn, Deepika Sirohi, Manish Kohli, Benjamin Louis Maughan, Umang Swami, Mark Yandell, Neeraj Agarwal
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P012.
https://doi.org/10.1158/1535-7163.TARG-21-P012
Published: 01 December 2021
View article titled, Abstract P012: Genomic and clinical correlates of overall survival (OS) in men with newly diagnosed metastatic castration-sensitive prostate cancer (mCSPC) undergoing intensified androgen deprivation therapy (ADT)
Journal Articles

Abstract C216: Phase 1, first‐in‐human, dose‐escalation study of EZN‐2208, a novel anticancer agent, in patients (pts) with advanced malignancies

Razelle Kurzrock, Jennifer Wheler, David S. Hong, Zhong Guo, Mary F. Mulcahy, Al B. Benson, III, Sanjay Goel, Umang Swami, Sridhar Mani, Aby Buchbinder
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): C216.
https://doi.org/10.1158/1535-7163.TARG-09-C216
Published: 10 December 2009
View article titled, Abstract C216: Phase 1, first‐in‐human, dose‐escalation study of EZN‐2208, a novel anticancer agent, in patients (pts) with advanced malignancies